Rostec State Corporation's Roseleс holding has developed an electrochemical system called "Biosensor" capable of detecting biomarkers of oncological diseases at an early stage. According to the state corporation, the device is made in the format of a microfluidic chip and is designed for mass use due to its low cost and ease of operation.
Diagnosis occurs by passing small volumes of blood or lymph through a system of microchannels, where nanostructured sensors detect the presence of target molecules. Rostec emphasized that the high sensitivity of the method allows for the detection of pathological changes long before the appearance of clinical symptoms. At the same time, the "Biosensor" does not require complex equipment and can be deployed in standard diagnostic laboratories.
Thus, oncology screening potentially becomes accessible without expensive PCR analyzers and tomographs. If clinical trials confirm the stated characteristics, the mass implementation of such chips can transform early cancer diagnosis from specialized research into a routine procedure.